Clavulanic Acid and Valproic Acid Synergy for Refractory Epilepsy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional anticonvulsant drugs like valproic acid are ineffective in controlling seizures in 30% of epilepsy patients, cause significant side effects, and worsen neuron lesions leading to motor and cognitive impairments, with poor medication compliance increasing the risk of seizures and status epilepticus.

Innovation Solution

A pharmaceutical composition combining clavulanic acid and valproic acid, administered in specific dosages and forms, to synergistically prevent seizures, decrease seizure intensity, and trigger neuroregeneration in the hippocampal dentate gyrus, effectively treating epilepsy-associated motor symptoms and cognitive impairments while reducing valproic acid dosage and side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If valproic acid is used as conventional anticonvulsant drug, then seizure prevention is achieved, but 30% of patients cannot be effectively controlled and side effects increase

Engineering Contradiction:

Improveseizure control effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines valproic acid with clavulanic acid to form a composite pharmaceutical composition. This combination merges the seizure prevention capability of valproic acid with the neuroprotective and pro-regenerative properties of clavulanic acid, achieving better seizure control in refractory patients while mitigating side effects through synergistic action.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention uses a composite pharmaceutical formulation containing both valproic acid and clavulanic acid. This composite material approach allows the combination of two drugs with complementary mechanisms of action, improving overall therapeutic efficacy while reducing dependence on high doses of valproic acid alone.

Inventive Principle:

Principle #40Composite materials

2Reliability

If valproic acid is administered continuously, then seizure prevention is maintained, but medication compliance becomes difficult and risk of status epilepticus increases

Engineering Contradiction:

Improveseizure prevention continuityVSAvoidmedication compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent maintains continuous therapeutic action through the combination formulation, where clavulanic acid provides sustained neuroprotection and neuronal regeneration support alongside valproic acid's seizure prevention. This continuous synergistic action helps maintain compliance by improving tolerability and reducing the need for complex dosing schedules.

Inventive Principle:

Principle #20Continuity of useful action

3Reliability

If valproic acid dosage is increased to control seizures, then seizure prevention improves, but burden on metabolic organs increases and side effects worsen

Engineering Contradiction:

Improveseizure controlVSAvoidmetabolic organ burden

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

Clavulanic acid acts as a complementary agent that enhances the therapeutic effect of valproic acid through synergistic mechanisms. This intermediary role allows for reduced valproic acid dosing while maintaining effective seizure control, thereby decreasing the metabolic burden on liver and kidneys.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the therapeutic parameter approach by introducing a second active ingredient (clavulanic acid) that modifies the dose-response relationship of valproic acid. This parameter change enables effective seizure control at lower valproic acid doses, reducing toxicities and metabolic strain.

Inventive Principle:

Principle #35Parameter changes

4Reliability

If conventional anticonvulsant drugs are used, then seizure prevention is achieved, but neuron lesion and cognitive impairment worsen

Engineering Contradiction:

Improveseizure preventionVSAvoidneuron lesion and cognitive impairment

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of conventional anticonvulsants on neurons into a benefit by adding clavulanic acid, which promotes neuronal regeneration and protects against lesions. This transformation turns the previously harmful neural impact into a protective and regenerative effect, especially in the hippocampal dentate gyrus.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The invention applies local quality by targeting specific brain regions (hippocampal dentate gyrus) for neuroregeneration and protection. Clavulanic acid selectively promotes neuronal growth and survival in this critical area, improving cognitive functions while maintaining seizure control, rather than having a uniform effect throughout the brain.

Inventive Principle:

Principle #3Local quality

Data Source

PatentEP3827821B1Use of pharmaceutical composition to treat epilepsy seizure and/or to treat epilepsy associated motor symptom and cognitive impairment

Publication Date: 2022.10.26 ARTHUR WISDOM TECH CONSULTANTS LTD

Figure 1~2
Figure 3
Figure 4a~4b

AI summary

The invention discloses a pharmaceutical composition, including clavulanic acid and valproic acid, for use in the treatment of epilepsy seizure and/or for use in the treatment of epilepsy-associated motor symptom and cognitive impairment. Clavulanic acid and valproic acid are to be co-administrated to a subject in need thereof.